(Editors' Note: This article covers a micro-cap stock. Please be aware of the risks associated with these stocks.)
Yesterday, Senesco Technologies (OTCQB:SNTI) reported positive results on its long-awaited cohort 3 in its phase...
Senesco Technologies, Inc. (“Senesco” or the “Company”) (OTCQB:SNTI)
reported results of cohort 3 in its Phase 1b/2a clinical study of
SNS01-T at the 55th American Society of Hematology Annual Meeting in New
Senesco Technologies, Inc. (“Senesco” or the “Company”) (OTC QB: SNTI)
reported today the completion of cohort 3 of its Phase 1b/2a clinical
trial for its drug, SNS01-T, for the treatment of multiple myeloma and
(MedPage Today) -- Children with systemic lupus erythematosus had an increased risk for cancer, particularly for malignancies that were hematologic in origin, analysis of data from a large clinical cohort showed.
Patrys Limited (ASX:PAB), a clinical stage biotechnology company
has announced that updated results from its PAT-SM6 Phase I/IIa clinical
trial in multiple myeloma (MM) will be presented at the 55th
American Society of...
(MedPage Today) -- The most common type of endometrial cancer occurred almost 80% more often in postmenopausal women who regularly consumed sugar-sweetened drinks as compared with women who consumed none, a large cohort study showed.
Isis Pharmaceuticals (NASDAQ: ISIS) announced today that it plans to add a 12 mg cohort to the ongoing Phase 1b/2a study evaluating ISIS-SMNRx in children with spinal muscular atrophy (SMA). In addition, a 12 mg dose will be included in an...
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.